STC Stem Cell Treatment & Research Institute (www.stcstri.com)
of STC Life Co., Ltd. (Chairman: Kye Ho Lee) succeeded in
differentiating new pluripotent stem cells without side effect into
beta-cells that control insulin in pancreas, after conducting research
projects for several years. These new pluripotent stem cells can be
differentiated into any tissues or organs without adverse effects.
Scientists at STC Stem Cell Treatment & Research Institute firstly
created new pluripotent stem cells with no adverse effects and induced
them to differentiate into beta-cells, and they identified their change
into beta-cells 7 days thereafter. Then they identified the generation
of intact beta-cells by tracing insulin genes that typically appear in
beta-cells.
Along with success in differentiation of beta-cells, they also succeeded
in differentiating into multiple cells in a short span of time. The
research team led by Dr. Lee Sang-Yeon said that they generated
beta-cells in these processes for the first time in the world.
The research outcome is expected to be immediately applied to treating
diabetes as it shows no adverse effects with outstanding safety.
“With development of technology that can successfully differentiate STC
pluripotent stem cells without side effects into beta-cells of pancreas,
physicians now can treat basic cause of diseases rather than simply
mitigating symptoms,” said Kye Ho Lee, Chairman of STC Life. “As we
developed natural substances-based pluripotent stem cells (We refer to
as STC EPN : Elicited pluripotent stem cell from natural compound) and
technology of differentiating diverse cells using such stem cells, after
successfully differentiating beta-cells for nerves, cartilages, liver,
bone, fat and pancreas, we will be able to lead the world stem cell
market. We will grow as the world’s top life science company by
developing cell therapies with leading technologies.”
Established in 1989, STC Life is a life science company that
concentrates on R&D of stem cells resources, genes related to
controlling active oxygen in body (p62), life sciences, and energy water
for agriculture.
STC Life developed Pluripotent stem cell without side effects, the first
of its kind in the world, and it obtained a total of 58 patents in Korea
and other countries, including 17 patents related with STC Pluripotent
stem cells. It is also a therapy-oriented life science company that is
treating incurable diseases and down-aging using mesenchymal stem cells
at 97.7 B&H Clinic.
With the mission of realizing vision and dream of bringing disease-free
healthy life to people and extending lifespan while creating the world
with no poverty, STC Life will continuously develop new technologies to
shape for the better future.
Copyright Business Wire 2014